Showing results (801-810 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1985
Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin)P Dodion, T A Davis, M Rozencweig, et al.
Investigational New Drugs|January 1, 1985
Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)L Pendyala, S Madajewicz, P J Creaven
Investigational New Drugs|January 1, 1985
Phase II trial of bisantrene in non-small cell lung cancerT P Miller, F R Ahmann, C Mackel, et al.
Investigational New Drugs|August 26, 2016
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patientsTeresa Di Desidero, Lisa Derosa, Luca Galli, et al.
Investigational New Drugs|March 19, 2010
Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell lineYuuka Takahashi, Masaharu Hazawa, Kenji Takahashi, et al.
Investigational New Drugs|April 9, 2021
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutationLin-Ling Jin, Zhen-Zhen Wu, Yan-Li Wang, et al.
Investigational New Drugs|April 15, 2021
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinomaStephen L Chan, Paul N M Cheng, Angela M Liu, et al.
Investigational New Drugs|May 31, 2014
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsQuentin Chalret du Rieu, Sylvain Fouliard, Mélanie White-Koning, et al.
Investigational New Drugs|June 4, 2014
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupKristen K Ciombor, Yang Feng, Al Bowen Benson, et al.
Investigational New Drugs|June 5, 2014
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumorsGordana Vlahovic, Vassiliki Karantza, Ding Wang, et al.
Pageof 372